You are here

psychedelics

MDMA Drug Developers Reprioritize Following Lykos Rejection in PTSD

BioSpace

Mon, 09/30/24 - 09:51 am

Lykos Therapeutics

After an FDA rejection, here’s what’s next in the psychedelics pipeline

BioPharma Dive

Wed, 08/28/24 - 11:41 am

Lykos Therapeutics

COMPASS Pathways

Incannex Healthcare

Article retractions muddy MDMA waters after FDA denial

Pharmaphorum

Mon, 08/12/24 - 11:23 am

Lykos Therapeutics

MDMA therapy is facing an imminent FDA decision. Here’s what you need to know

Stat

Fri, 08/9/24 - 11:29 am

Lykos Therapeutics

AbbVie joins psychedelic push, inks $2B+ next-gen neuro deal with Gilgamesh

Fierce Biotech

Mon, 05/13/24 - 10:21 pm

Gilgamesh Pharmaceuticals

Reunion raises over $100M to build a better psychedelic drug

BioPharma Dive

Fri, 05/3/24 - 11:18 am

Reunion Neuroscience

postpartum depression

Cybin CEO on FDA breakthrough designation for psychedelic drug treating MDD

Medical Marketing and Media

Mon, 04/1/24 - 11:48 am

major depressive disorder

After crunching 70k 'trip reports', Mindstate looks to test first AI-derived psychedelic on humans

Fierce Biotech

Wed, 03/13/24 - 10:31 pm

artificial intelligence

machine learning

First-ever drug application for MDMA finally reaches FDA after near 40-year journey

Fierce Biotech

Thu, 12/14/23 - 09:51 am

A startup’s psychedelic delivery tech is grabbing attention. Will pharma listen?

Pharma Voice

Tue, 09/5/23 - 11:20 am

FDA discloses its first draft guidance on psychedelic trials

Clinical Trials Arena

Mon, 06/26/23 - 09:47 am

clinical trials

Psychedelics startup nets more than $10M in seed funding as it looks to make a splash

Endpoints

Tue, 08/23/22 - 10:25 am

Freedom Biosciences

major depressive disorder